[Depot insulin with tumor risk. Changing now or staying cool? (interview by Sarah Pampel)].
Spranger
Joachim
J
D015982:Bias; D001943:Breast Neoplasms / Q000139:chemically induced; D002986:Clinical Trials as Topic / Q000706:statistics & numerical data; D003692:Delayed-Action Preparations; D003920:Diabetes Mellitus / Q000188:drug therapy*; D005260:Female; D006801:Humans; D007004:Hypoglycemic Agents / Q000009:adverse effects* / Q000627:therapeutic use; D007328:Insulin / Q000009:adverse effects / Q000031:analogs & derivatives* / Q000627:therapeutic use; D000069036:Insulin Glargine; D049528:Insulin, Long-Acting; D008297:Male; D009369:Neoplasms / Q000139:chemically induced*; D012306:Risk
D003692:Delayed-Action Preparations; D007004:Hypoglycemic Agents; D007328:Insulin; D049528:Insulin, Long-Acting; D000069036:Insulin Glargine